Acorda Therapeutics Inc. (ACOR)

3.86
NASDAQ : Health Technology
Prev Close 3.85
Day Low/High 3.77 / 4.08
52 Wk Low/High 2.27 / 21.63
Avg Volume 1.48M
Exchange NASDAQ
Shares Outstanding 48.08M
Market Cap 185.10M
EPS 0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acorda Therapeutics To Host Conference Call To Discuss First Quarter 2015 Financial Results On April 30, 2015

Acorda Therapeutics To Host Conference Call To Discuss First Quarter 2015 Financial Results On April 30, 2015

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that it will host a conference call and webcast to report its first quarter 2015 financial results on Thursday, April 30 at 8:30 a.

Acorda Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy Of Neurology Annual Meeting

Acorda Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy Of Neurology Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today presented data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS).

Acorda Therapeutics Named One Of The Best Places To Work For In New York 2015

Acorda Therapeutics Named One Of The Best Places To Work For In New York 2015

Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named one of the best companies to work for in New York, based on an independent survey by the Best Companies Group (BCG).

ACOR Crosses Above Key Moving Average Level

ACOR Crosses Above Key Moving Average Level

In trading on Tuesday, shares of Acorda Therapeutics Inc crossed above their 200 day moving average of $35.00, changing hands as high as $35.41 per share. Acorda Therapeutics Inc shares are currently trading up about 1.6% on the day.

'Mad Money' Lightning Round: I Don't Like Caterpillar, Buy TG Therapeutics

'Mad Money' Lightning Round: I Don't Like Caterpillar, Buy TG Therapeutics

Cramer likes JPMorgan Chase almost as much as Wells Fargo but isn't crazy about Zagg.

Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind

Jim Cramer's 'Mad Money' Recap: This Maddening Market Can't Make Up Its Mind

The trend is not your friend in this market because there is no trend, Cramer says.

Acorda Therapeutics Ringing The Opening Bell At The NASDAQ Stock Exchange, March 16, 2015 (Photo: Business Wire)

Acorda Therapeutics Ringing The Opening Bell At The NASDAQ Stock Exchange, March 16, 2015 (Photo: Business Wire)

Acorda Therapeutics, Inc. (Nasdaq: ACOR) rang today's Opening Bell at the NASDAQ Stock Exchange to recognize the 20 th anniversary of the Company's incorporation.

Acorda Therapeutics Stock Sees Short Interest Jump 13.3%

Acorda Therapeutics Stock Sees Short Interest Jump 13.3%

The most recent short interest data has been released by the NASDAQ for the 02/27/2015 settlement date, which shows a 873,421 share increase in total short interest for Acorda Therapeutics Inc , to 7,434,503, an increase of 13.31% since 02/13/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda To Present New Analyses Of Cimaglermin Alfa (GGF2) Data At The 64th Annual ACC Scientific Session

Acorda To Present New Analyses Of Cimaglermin Alfa (GGF2) Data At The 64th Annual ACC Scientific Session

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will present new analyses of data from a Phase 1 clinical trial of cimaglermin alfa (GGF2), an investigative drug for heart failure, at the American College of Cardiology 64 th Annual...

Acorda Therapeutics To Present At The Barclays Global Healthcare Conference

Acorda Therapeutics To Present At The Barclays Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 11 at 1:35pm.

Notable Two Hundred Day Moving Average Cross - ACOR

Notable Two Hundred Day Moving Average Cross - ACOR

In trading on Friday, shares of Acorda Therapeutics Inc crossed below their 200 day moving average of $34.78, changing hands as low as $33.08 per share. Acorda Therapeutics Inc shares are currently trading off about 5.2% on the day.

Acorda Therapeutics To Present At The Cowen 35th Annual Health Care Conference

Acorda Therapeutics To Present At The Cowen 35th Annual Health Care Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, President and Chief Executive Officer, will present at the Cowen 35th Annual Health Care Conference in Boston on Monday, March 2 at 2:10pm.

'Mad Money' Lightning Round: Don't Gamble on Las Vegas Sands

'Mad Money' Lightning Round: Don't Gamble on Las Vegas Sands

Cramer's buying Schlumberger, is avoiding Marketo and can't figure out GoPro.

Jim Cramer's 'Mad Money' Recap: Forget Buffett, Think for Yourself

Jim Cramer's 'Mad Money' Recap: Forget Buffett, Think for Yourself

If you can't do your own homework, go buy an index fund, Cramer says, and don't blindly follow Warren Buffett.

Acorda Therapeutics (ACOR) Downgraded From Buy to Hold

Acorda Therapeutics (ACOR) Downgraded From Buy to Hold

Acorda Therapeutics (ACOR) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.

Acorda Therapeutics To Present At The 2015 RBC Capital Markets' Healthcare Conference

Acorda Therapeutics To Present At The 2015 RBC Capital Markets' Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, President and Chief Executive Officer, will present at the RBC Capital Markets' Healthcare Conference in New York on Tuesday, February 24 at 11:00am.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMCX, BBW, BWL.A, MSLI, NCIT, TKR, VSH Downgrades: ACOR, APA, BCOR, CMSB, IGTE, K, KRFT, LEE, MHFI, PIR, SPRT, SPW, TKC, TOWR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Acorda Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

Acorda Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the fourth quarter and full year ended December 31, 2014.

3 Big-Volume Stocks to Trade for Breakouts: First Solar and More

3 Big-Volume Stocks to Trade for Breakouts: First Solar and More

These stocks rising on unusual volume are within range of triggering breakout trades.

Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today

Acorda Therapeutics (ACOR) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Acorda Therapeutics To Present At The 2015 Leerink Global Healthcare Conference

Acorda Therapeutics To Present At The 2015 Leerink Global Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief Scientific Officer, will present at the 2015 Leerink Global Healthcare Conference in New York...

Acorda Therapeutics To Host Conference Call To Discuss Fourth Quarter And Year End 2014 Financial Results On February 12, 2015

Acorda Therapeutics To Host Conference Call To Discuss Fourth Quarter And Year End 2014 Financial Results On February 12, 2015

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will host a conference call and live webcast to report its fourth quarter and year end 2014 financial results on Thursday, February 12 at 8:30 a.

Acorda Announces Safety And Tolerability Data From First Clinical Trial Of Remyelinating Antibody In Multiple Sclerosis

Acorda Announces Safety And Tolerability Data From First Clinical Trial Of Remyelinating Antibody In Multiple Sclerosis

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS).

Acorda Therapeutics (ACOR) Reaches New Lifetime High Today

Acorda Therapeutics (ACOR) Reaches New Lifetime High Today

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a new lifetime high candidate

Jim Cramer's Top Stock Picks: ISIS CELG NPSP AA ACOR

Jim Cramer's Top Stock Picks: ISIS CELG NPSP AA ACOR

Cramer remains a big fan of Alcoa and thinks Acorda Therapeutics is exactly what investors should be looking for in a growth stock.

Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses

Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses

The restaurants and the biotechs tried their best to save us but it just wasn't enough, Cramer says.

First Week of ACOR February 20th Options Trading

First Week of ACOR February 20th Options Trading

Investors in Acorda Therapeutics Inc saw new options become available this week, for the February 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new February 20th contracts and identified one put and one call contract of particular interest.

Acorda Provides Corporate Update At J.P. Morgan Healthcare Conference

Acorda Provides Corporate Update At J.P. Morgan Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2014 were $109 million, and unaudited AMPYRA 2014...

Today's Strong And Under The Radar Stock Is Acorda Therapeutics (ACOR)

Today's Strong And Under The Radar Stock Is Acorda Therapeutics (ACOR)

Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a strong and under the radar candidate

Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

Study results from the most important drug in Biogen Idec's pipeline are expected as early as Monday. Here are essential points you need to know.

TheStreet Quant Rating: D (Sell)